DexCom (NASDAQ:DXCM) EVP Jon Coleman Sells 4,912 Shares

DexCom, Inc. (NASDAQ:DXCM) EVP Jon Coleman sold 4,912 shares of DexCom stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total transaction of $358,576.00. Following the transaction, the executive vice president directly owned 100,361 shares in the company, valued at $7,326,353. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jon Coleman also recently made the following trade(s):

• On Thursday, June 4th, Jon Coleman sold 4,911 shares of DexCom stock. The stock was sold at an average price of $74.13, for a total transaction of $364,052.43.

DexCom Trading Up 0.4%

DXCM stock opened at $72.86 on Friday. The company has a market capitalization of $28.11 billion, a PE ratio of 31.14, a price-to-earnings-growth ratio of 1.14 and a beta of 1.45. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company’s 50 day moving average price is $64.83 and its two-hundred day moving average price is $66.98. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business’s revenue was up 15.0% compared to the same quarter last year. During the same period last year, the firm posted $0.32 earnings per share. As a group, analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on DXCM shares. Bank of America decreased their target price on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Truist Financial reaffirmed a “buy” rating and issued a $80.00 target price (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Stifel Nicolaus set a $90.00 target price on shares of DexCom and gave the stock a “buy” rating in a research note on Friday. William Blair raised shares of DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Finally, Benchmark started coverage on shares of DexCom in a research note on Monday, May 11th. They issued a “buy” rating and a $77.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $82.63.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Avidity Partners Management LP bought a new stake in DexCom in the first quarter valued at $5,652,000. Glenmede Trust Co. NA boosted its holdings in DexCom by 36.7% in the first quarter. Glenmede Trust Co. NA now owns 394,751 shares of the medical device company’s stock valued at $24,790,000 after acquiring an additional 105,928 shares in the last quarter. Wellington Grp LLC boosted its holdings in DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 475 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in DexCom by 32.3% in the first quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock valued at $166,077,000 after acquiring an additional 645,534 shares in the last quarter. Finally, Centaurus Financial Inc. bought a new stake in DexCom in the first quarter valued at $943,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom announced it will highlight new clinical findings, product advancements, and strategic initiatives at ADA 2026, reinforcing its case for broader CGM adoption and earlier-stage diabetes intervention. Article: Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
• Positive Sentiment: Recent commentary remained constructive, with analysts and market coverage noting DexCom’s strong Q1 momentum, global CGM growth potential, and expanding international demand, which may help support the stock. Article: Here’s Why You Should Retain DexCom Stock in Your Portfolio
• Positive Sentiment: DexCom also said it plans to acquire wellness tracking company Nutrisense and launch an enhanced Stelo app, a move that could broaden its consumer health footprint and create new engagement opportunities. Article: Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app
• Neutral Sentiment: DexCom EVP Jon Coleman sold shares in two transactions under a pre-arranged 10b5-1 plan. While the sales were disclosed as routine, insider selling can still weigh on sentiment. Article: SEC Form 4 filing
• Neutral Sentiment: Separate market commentary noted DexCom has lagged the Dow over the past year, even as analysts remain bullish on its longer-term outlook. Article: Is DexCom Stock Underperforming the Dow?

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.